We are international
• treatment options TEXT SIZE   
Clinical Trials

Kyprolis, a next-generation proteasome inhibitor, received expanded FDA approval in January, 2016. It is now approved in combination with dexamethasone, or with Revlimid(R) (lenalidomide) + dexamethasone, for the treatment of patients with relapsed or refractory myeloma who have received 1 to 3 prior lines of therapy. It is also approved as a single agent for the treatment of relapsed or refractory myeloma patients who have had 1 or more lines of therapy.

General Information
Clinical Trials
Blogs and Press Releases
ARROW Clinical Trial
Fact Sheet
A Randomized, Open-label, Phase III Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
A Fact Sheet
Phase III Study with Carfilzomib & Dexamethasone vs Velcade & Dexamethasone for Relapsed MM Patients. Sites actively opening, so call the Hotline for the most up-to-date listings.

The ENDEAVOR TRIAL on clinicaltrials.gov
Open Carfilzomib Trials